NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aligos Therapeutics, Inc. (ALGS) Stock Analysis

Aligos Therapeutics, Inc. (ALGS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALGS

$4.96

−$0.07 (−1.39%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALGS with… →

ALGS Key Statistics

As of Oct 21, 2026
Trading
Open
$4.88
Previous Close
$5.03
Day's Range
4.88–5.23
52-Week Range
3.98–13.69
Volume
13.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.36
Valuation
Market Cap
$30.97M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.98
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.41
Financials (FY)
Revenue (FY)
$2.19M−44.59%
Net Income (FY)
−$24.19M
Profit marginThe share of revenue left as profit after all costs and taxes.
−241.01%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.44M
1-Year Return
−52.72%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
83.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALGS closed at $4.96, −52.72% over 1 year.

Aligos Therapeutics, Inc. (ALGS) has a market capitalization of $30.97M.

In fiscal 2025, ALGS reported revenue of $2.19M.

ALGS Stock Return by Calendar Year

Aligos Therapeutics, Inc. (ALGS) return since Oct 2020: what $10,000 became

1 year
$10,000 $4,728
−52.72%
5 years
$10,000 $126
−98.74%
Since Oct 2020
$10,000 $134
−98.66%

If you had invested $10,000 in Aligos Therapeutics, Inc. (ALGS) at the close on October 16, 2020, the earliest close on record here, it would have been worth $134 at the close on October 21, 2026: −98.66% in total, −51.22% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.78%
2025−76.61%
2024+140.00%
2023−30.33%
2022−91.97%
2021−57.07%
2020 (partial year)+86.20%

As of October 21, 2026.

ALGS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.19M−$24.19M−1,106.7%
2024$3.95M−$131.21M−3,326.0%
2023$15.53M−$87.68M−564.6%
2022$13.91M−$96.05M−690.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.19M—−$87.99M−$24.19M−1,106.7%
2024$3.95M—−$89.15M−$131.21M−3,326.0%
2023$15.53M—−$88.13M−$87.68M−564.6%
2022$13.91M—−$97.58M−$96.05M−690.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ALGS Valuation vs Biotechnology Median

Median of 608 stocks
MetricALGSBiotechnology medianvs median
P/S ratio0.9813.300.1x the median
Profit margin−241.01%−38.31%202.7 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aligos Therapeutics, Inc. (ALGS) carries a market capitalisation of $30.97M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 82.

Over the past 52 weeks the price has ranged from $3.98 to $13.69. The most recent close on file for ALGS is $4.96, dated October 21, 2026. That is −$0.07 (−1.39%) against the previous close. The latest close sits 24.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.19M. That is −44.59% against the prior fiscal year, when revenue was $3.95M. The same year closed with a net loss of $24.19M. The reported profit margin is −241.01%. That is 202.7 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −7.41.

Across the 4 fiscal years on file, revenue moves from $13.91M in 2022 to $2.19M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 0.98. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −52.72%. Measured over 5 years, that is −58.32% a year compounded. The reported beta is 2.36. Annualized volatility over the trailing 6 years is 99.83%.

Growth & Income

No dividend is on file for ALGS.

Across the complete calendar years on file, 2024 returned +140.00% and 2022 returned −91.97%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −46.78%.

Peer Comparison

Aligos Therapeutics, Inc. (ALGS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aligos Therapeutics, Inc. ALGS $30.97M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aligos Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Visit website →